---
title: "CRISPR Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 10.18 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294735075.md"
datetime: "2026-08-03T20:30:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294735075.md)
  - [en](https://longbridge.com/en/news/294735075.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294735075.md)
generator: "portal-rs"
---

# CRISPR Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 10.18 M

Revenue: As of FY2026 Q2, the actual value is USD 10.18 M, beating the estimate of USD 7.43 M.

EPS: As of FY2026 Q2, the actual value is USD -0.94, beating the estimate of USD -1.1714.

EBIT: As of FY2026 Q2, the actual value is USD -90.19 M.

The provided reference, a Form 8-K filed by CRISPR Therapeutics AG, announces the release of its financial results for the quarter ended June 30, 2026, and other business highlights on August 3, 2026. However, the document explicitly states that actual financial and operational metrics, as well as any outlook or guidance, are not included within this document . Therefore, no specific financial metrics, operational metrics, or outlook information can be extracted from the provided text.

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)

## Related News & Research

- [CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data](https://longbridge.com/en/news/297413766.md)
- [CRISPR Therapeutics (NASDAQ:CRSP) Earns Market Outperform Rating from Citizens Jmp](https://longbridge.com/en/news/296922645.md)
- [What smart people are saying about Trump's acquisition of Venezuelan oil](https://longbridge.com/en/news/297464534.md)
- [Trump to meet with oil execs about cutting gas prices, as his Venezuelan SPR plan faces skepticism](https://longbridge.com/en/news/297545089.md)
- [Trump Calls Venezuelan Oil a 'Gift' to Americans, Says It Will Refill Strategic Petroleum Reserve Biden 'Virtually Emptied'](https://longbridge.com/en/news/297468424.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**